HLB Pharmaceutical Co. Ltd Capital Reinvestment Ratio
HLB Pharmaceutical Co. Ltd capital reinvestment ratio. HLB Pharmaceutical Co. Ltd (047920) has a Capital Reinvestment Ratio of 1.21x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩1.86 Billion) in capital expenditures (₩2.26 Billion). See 047920 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of HLB Pharmaceutical Co. Ltd (2014–2024)
Capital reinvestment ratio of HLB Pharmaceutical Co. Ltd from 2014 to 2024. This chart tracks HLB Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 3 annual periods. See how financially flexible is HLB Pharmaceutical Co. Ltd to measure the company's free cash flow as a share of total liabilities.
HLB Pharmaceutical Co. Ltd Capital Reinvestment Ratio by Year (2014–2024)
HLB Pharmaceutical Co. Ltd capital reinvestment ratio by year from 2014 to 2024. For the full cash flow conversion analysis, see HLB Pharmaceutical Co. Ltd (047920) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | ₩6.84 Billion | ₩3.09 Billion | ▼ -56.2% |
| 2019 | 1.03x | ₩1.35 Billion | ₩1.40 Billion | ▼ -29.6% |
| 2014 | 1.47x | ₩1.54 Billion | ₩2.26 Billion | — |